about
Anti-angiogenic therapies for metastatic colorectal cancerAnti-angiogenic therapy for metastatic colorectal cancerDesigning a broad-spectrum integrative approach for cancer prevention and treatment.Angiostatin inhibits pancreatic cancer cell proliferation and growth in nude mice.Expression of angiostatin cDNA in human gallbladder carcinoma cell line GBC-SD and its effect on endothelial proliferation and growth.Tumor-derived VEGF modulates hematopoiesisNaturally occurring human plasminogen, like genetically related apolipoprotein(a), contains oxidized phosphatidylcholine adducts.Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.The role of angiogenesis in the pathology of multiple sclerosis.Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.Murine experimental autoimmune encephalomyelitis is diminished by treatment with the angiogenesis inhibitors B20-4.1.1 and angiostatin (K1-3)Therapeutic advances in women's cancersCombination angiostatic therapy completely inhibits ocular and tumor angiogenesis.Survival of chronic lymphocytic leukemia cells: CD40L and the vascular endothelial growth factor (VEGF) connection.Dose-response relationship of ultrasound contrast agent in an in vivo murine melanoma modelAnti-angiogenic therapy: Prospects for treatment of ocular tumors.Antiangiogenic therapy in human gastrointestinal malignancies.The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.Novel antibodies as anticancer agents.Angiogenesis inhibitors and the need for anti-angiogenic therapeutics.Disruption of the thrombospondin-2 gene alters the lamellar morphology but does not permit vascularization of the adult mouse lumbar disc.The renin-angiotensin system and malignancy.High efficacy and minimal peptide required for the anti-angiogenic and anti-hepatocarcinoma activities of plasminogen K5.The Notch ligand Delta-like 4 (DLL4) as a target in angiogenesis-based cancer therapy?Therapy innovation for the treatment of pancreatic neuroendocrine tumors.TWEAK/Fn14 signaling in tumors.Magnetic resonance angiography visualization of abnormal tumor vasculature in genetically engineered mice.Antisense HIF-1alpha prevents acquired tumor resistance to angiostatin gene therapy.Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies.Marine algal carotenoids inhibit angiogenesis by down-regulating FGF-2-mediated intracellular signals in vascular endothelial cells.Cell adhesion and cancer: is there a potential for therapeutic intervention?
P2860
Q24241813-67D075F4-716E-4476-81EB-D1422F0B4B71Q24243297-0DA7E99E-61F8-4D5B-870B-B01BF865AB3DQ30736359-942E54C6-B968-48B1-9F2C-CE1B8DF40476Q33222336-BF5E00F7-4AE9-405B-897B-44ECFBE3CBBAQ33244333-F844F7C7-4FF5-45F2-AE15-9B02F8B5185EQ33592159-EBDB0491-A142-4436-AB00-4F919977B8CDQ33886478-CC519754-F870-43DF-937A-F8B748113B82Q34271190-DF31EA03-1CD4-45B7-A835-B6CAECA816A2Q34620249-B2F53AD9-90BE-4418-BD75-00B0CA3F20CCQ34620545-14ADBF2D-B7D3-40FB-9689-511F529ADD1BQ35108066-01B0BF4C-39C0-4FA5-84BC-13E296B62292Q35418973-7CF95708-A3B1-4AA5-8679-8085874CC5D1Q35575003-BC949980-733E-4EBD-BDA1-C24330C9C63DQ36110555-E05E6C24-BDE7-4E78-B36C-5B47293A5E17Q36295224-ACDA53A4-F26D-4ACF-AD2A-F4B0A048FBCBQ36567094-F2C92E56-301D-43AA-91E0-552E94ED7CB3Q36591067-93401BC7-A0E5-4D6C-87C1-E946E2CB944DQ36616812-6EE522C0-A7E6-4DA5-94B2-4BA7F13D54AEQ36832141-121F1DB8-7E5B-4ADF-A306-A0C1EC080D2EQ36949560-45285A10-9C21-40C0-8D5E-9D7D99A3B44EQ36955323-E8DA4447-FFE1-497B-B85F-6CC9A718E3CCQ37218569-AF325B9E-6864-475F-9292-FD10DADDEAD5Q37295399-382A7C45-5367-49AC-87BA-69984BC6E362Q37601970-F27F5BFD-6F94-4F24-A4A4-8835CC029483Q37988905-30E81BD9-D779-4A16-A9D4-217745139631Q38668064-FAC3D9AD-7797-4FAB-B666-0400FCB4C333Q39233014-9D310639-696F-4393-9680-9526C284E98DQ39721643-8A2FDB19-9F3F-4714-A081-46EF64F4DFF9Q40411720-6DC3D3EE-B953-471F-A603-F25883B8B571Q43776835-C9358BEE-642C-4BAE-BE74-38BF50318AF1Q52579142-406DC641-2FE8-459F-8B3E-76173EC3924C
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Antiangiogenic cancer therapy.
@ast
Antiangiogenic cancer therapy.
@en
type
label
Antiangiogenic cancer therapy.
@ast
Antiangiogenic cancer therapy.
@en
prefLabel
Antiangiogenic cancer therapy.
@ast
Antiangiogenic cancer therapy.
@en
P1476
Antiangiogenic cancer therapy.
@en
P2093
P304
P356
10.1016/J.SEMCANCER.2003.09.018
P577
2004-04-01T00:00:00Z